BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 12469211)

  • 1. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction.
    Liu D; Xu JK; Figliomeni L; Huang L; Pavlos NJ; Rogers M; Tan A; Price P; Zheng MH
    Int J Mol Med; 2003 Jan; 11(1):17-21. PubMed ID: 12469211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin.
    Nagasawa T; Kobayashi H; Kiji M; Aramaki M; Mahanonda R; Kojima T; Murakami Y; Saito M; Morotome Y; Ishikawa I
    Clin Exp Immunol; 2002 Nov; 130(2):338-44. PubMed ID: 12390325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression in human gingival fibroblasts and periodontal ligament cells.
    Belibasakis GN; Johansson A; Wang Y; Chen C; Kalfas S; Lerner UH
    Infect Immun; 2005 Jan; 73(1):342-51. PubMed ID: 15618171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis.
    Crotti T; Smith MD; Hirsch R; Soukoulis S; Weedon H; Capone M; Ahern MJ; Haynes D
    J Periodontal Res; 2003 Aug; 38(4):380-7. PubMed ID: 12828654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
    Huang L; Xu J; Wood DJ; Zheng MH
    Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis.
    Mogi M; Otogoto J; Ota N; Togari A
    J Dent Res; 2004 Feb; 83(2):166-9. PubMed ID: 14742657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3.
    Zhang D; Yang YQ; Li XT; Fu MK
    Arch Oral Biol; 2004 Jan; 49(1):71-6. PubMed ID: 14693199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of baicalin on the expression of receptor activator of nuclear factor-kappaB ligand in cultured human periodontal ligament cells.
    Wang GF; Wu ZF; Wan L; Wang QT; Chen FM
    Pharmacology; 2006; 77(2):71-7. PubMed ID: 16636611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTH differentially regulates expression of RANKL and OPG.
    Huang JC; Sakata T; Pfleger LL; Bencsik M; Halloran BP; Bikle DD; Nissenson RA
    J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
    Grimaud E; Soubigou L; Couillaud S; Coipeau P; Moreau A; Passuti N; Gouin F; Redini F; Heymann D
    Am J Pathol; 2003 Nov; 163(5):2021-31. PubMed ID: 14578201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
    Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
    Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples.
    Seck T; Diel I; Bismar H; Ziegler R; Pfeilschifter J
    Eur J Endocrinol; 2001 Aug; 145(2):199-205. PubMed ID: 11454517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
    Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
    Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
    J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease.
    Valverde P; Kawai T; Taubman MA
    J Bone Miner Res; 2004 Jan; 19(1):155-64. PubMed ID: 14753747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.